Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: Left atrial appendage occlusion (LAAO) at the time of implantation may reduce thromboembolic events (TEs) during continuous-flow left ventricular assist device support. The HeartMate 3 (HM3) reduces TEs overall, but the efficacy of LAAO in HM3 is unknown.
Methods: Adults receiving first HM3 implantation from November 2014 through December 2019 at a single, large medical centre were retrospectively reviewed. TEs included device thrombosis and ischaemic stroke. Patients were classified by whether they received LAAO or not. Incidence of TEs was compared between groups using cumulative incidence curves with competing risks (death and heart transplant) and risk factors for TEs were assessed with Fine and Gray competing risk regression.
Results: A total of 182 patients received HM3, of whom 99 (54%) received LAAO versus 83 (46%) who did not. There were 14 TEs, including 13 strokes (7%) and 1 pump thrombosis (0.5%). No significant difference in the incidence of TEs in each group was found (Gray's test: P = 0.35). LAAO was not associated with TEs in multivariable Fine-Gray analysis (P = 0.10) and no significant risk factors for TEs were found. There were zero disabling strokes in those who received LAAO compared to 6 (7%) in those who did not receive LAAO (P = 0.008).
Conclusions: A low number of TEs was observed in HM3 recipients. LAAO did not further reduce the overall rate of TEs in this patient population, though its use may be beneficial in preventing disabling ischaemic strokes after HM3 implantation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972327 | PMC |
| http://dx.doi.org/10.1093/icvts/ivab285 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Left atrial appendage occlusion: real world observational data on in-hospital results, clinical outcome and hemoglobin level.
Scand Cardiovasc J
December 2025
Department of Internal Medicine, Division of Cardiology, Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany.
Background: Interventional left atrial appendage occlusion (LAAO) was developed as a treatment option for patients who cannot receive traditional anticoagulation therapies. To date, randomized study data on this treatment are still limited, so registries and other non-randomized studies may help define the role of LAAO in clinical practice.
Design: We performed LAAO consecutively on 599 patients.
Left Atrial Appendage Occlusion Compared to Anticoagulation in Patients Suffering from Atrial Fibrillation with Advanced Chronic Kidney Disease.
J Clin Med
August 2025
Servicio de Cardiología, Complejo Asistencial Universitario de Salamanca (CAUSA), Universidad de Salamanca (USAL), 37007 Salamanca, Spain.
: Chronic kidney disease (CKD) is a significant risk factor for thrombogenic and bleeding events in patients with atrial fibrillation (AF). Left atrial appendage occlusion (LAAO) is increasingly utilized as an alternative to oral anticoagulation. We aimed to compare LAAO against medical therapy in advanced CKD patients (A-CKD).
View Article and Find Full Text PDFSafety of cardioversion without anticoagulation in patients' status post left atrial appendage occlusion: A systematic review and meta-analysis.
Cardiovasc Revasc Med
August 2025
Department of Cardiovascular Medicine, Baystate Medical Center and Division of Cardiovascular Medicine, University of Massachusetts Baystate, Springfield, MA, USA.
Background: Direct current cardioversion (DCCV) is commonly used for rhythm control in atrial fibrillation (AF). Left atrial appendage occlusion (LAAO) provides stroke prevention in patients with contraindications to oral anticoagulation (OAC), but the safety of DCCV without periprocedural anticoagulation in this group remains uncertain.
Objective: To evaluate the safety of performing DCCV without systemic anticoagulation in patients with prior LAAO.
Clinical evaluation of a novel fixed-dose combination tablet (Sentorphil ForteGold) versus compounded powdered medications in dogs with myxomatous mitral valve disease: a randomized, double-blind study.
Front Vet Sci
August 2025
Hyun Changbaig Animal Heart Institute, VIP Animal Medical Center, Seoul, Republic of Korea.
Introduction: Myxomatous mitral valve disease (MMVD) is a prevalent cardiac condition in older, small-breed dogs, often managed with multiple medications. Traditional administration involves compounded powdered mixtures, which may lead to dosing inaccuracies and reduced compliance.
Methods: In a randomized, double-blind clinical trial, 60 client-owned dogs diagnosed with ACVIM stage C MMVD were assigned to receive either a novel fixed-dose combination tablet (Sentorphil ForteGold) or a compounded powdered mixture of torsemide, pimobendan, enalapril, and spironolactone.
Safety and Feasibility of Atrial Fibrillation Ablation and Left Atrial Appendage Occlusion at Centers With Versus Without Onsite Cardiothoracic Surgery.
J Cardiovasc Electrophysiol
August 2025
Division of Cardiology, Rooney Heart Institute at NCH Healthcare System, Naples, Florida, USA.
Background: Atrial fibrillation (AF) ablation and left atrial appendage occlusion (LAAO) are traditionally performed in centers with onsite cardiothoracic surgery (CTS), expanding these procedures to centers without CTS (Wo-CTS) raises questions about procedural safety and feasibility.
Objective: To compare the safety and feasibility of AF ablation and LAAO at two centers within the Naples Comprehensive Healthcare (NCH) System in Southwest Florida, one with CTS and the other Wo-CTS.
Methods: A retrospective cohort study was conducted for consecutive patients between March 1, 2023, to May 31, 2025.